{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:31:39Z","timestamp":1793039499225,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,21]],"date-time":"2014-09-21T00:00:00Z","timestamp":1411257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11940-014-0319-0","type":"journal-article","created":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T01:43:32Z","timestamp":1411177412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Treatment of Frontotemporal Dementia"],"prefix":"10.1007","volume":"16","author":[{"given":"Richard M.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,21]]},"reference":[{"key":"319_CR1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/11640070-000000000-00000","volume":"26","author":"R Seltman","year":"2012","unstructured":"Seltman R, Matthews B. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26:841\u201370. Excellent review article of FTLD syndromes.","journal-title":"CNS Drugs"},{"key":"319_CR2","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011;134:2456\u201377.","journal-title":"Brain"},{"key":"319_CR3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, HIllis A, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314.","journal-title":"Neurology"},{"key":"319_CR4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"M Armstrong","year":"2013","unstructured":"Armstrong M, Litvan I, Lang A, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503.","journal-title":"Neurology"},{"key":"319_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszeweski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1\u20139.","journal-title":"Neurology"},{"key":"319_CR6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","volume":"23","author":"DW Dickson","year":"2010","unstructured":"Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394\u2013400.","journal-title":"Curr Opin Neurol"},{"key":"319_CR7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"B Brooks","year":"2000","unstructured":"Brooks B, Miller R, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"319_CR8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/01.wnl.0000172911.39167.b6","volume":"65","author":"G Ringholz","year":"2005","unstructured":"Ringholz G, Appel S, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586.","journal-title":"Neurology"},{"key":"319_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","volume":"119","author":"IR Mackenzie","year":"2010","unstructured":"Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1\u20134.","journal-title":"Acta Neuropathol"},{"key":"319_CR10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(04)00767-7","volume":"3","author":"L Fratiglioni","year":"2004","unstructured":"Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343.","journal-title":"Lancet Neurol"},{"key":"319_CR11","unstructured":"US National Institute of Health Clinical Trials Registry 2013. Available at http:\/\/clinicaltrials.gov\/show\/NCT00382824 . Accessed 23 Jul 2014."},{"key":"319_CR12","doi-asserted-by":"crossref","first-page":"93107","DOI":"10.2165\/00002512-200421140-00003","volume":"21","author":"R Moretti","year":"2004","unstructured":"Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:93107.","journal-title":"Drugs Aging"},{"key":"319_CR13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178\u201385.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"319_CR14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","volume":"15","author":"MF Mendez","year":"2007","unstructured":"Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatr. 2007;15:84\u20137.","journal-title":"Am J Geriatr Psychiatr"},{"key":"319_CR15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1447-0594.2012.00956.x","volume":"13","author":"T Kimura","year":"2013","unstructured":"Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int. 2013;13:506\u20137.","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"319_CR16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.410260318","volume":"26","author":"I Litvan","year":"1989","unstructured":"Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26(3):404\u20137.","journal-title":"Ann Neurol"},{"issue":"2","key":"319_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1600-0404.2001.103002123.x","volume":"103","author":"G Fabbrini","year":"2001","unstructured":"Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103(2):123\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"319_CR18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.57.3.467","volume":"57","author":"I Litvan","year":"2001","unstructured":"Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467\u201373.","journal-title":"Neurology"},{"issue":"1","key":"319_CR19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jalz.2009.04.1231","volume":"6","author":"I Liepelt","year":"2010","unstructured":"Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70\u20134.","journal-title":"Alzheimers Dement"},{"key":"319_CR20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/gps.1973","volume":"23","author":"J Diehl-Schmid","year":"2008","unstructured":"Diehl-Schmid J, F\u00f6rstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatr. 2008;23:754\u20139.","journal-title":"Int J Geriatr Psychiatr"},{"key":"319_CR21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WAD.0b013e318047df5d","volume":"21","author":"MM Swanberg","year":"2007","unstructured":"Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21:164\u20136.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"319_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/WAD.0b013e318197852f","volume":"23","author":"AL Boxer","year":"2009","unstructured":"Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"319_CR23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","volume":"23","author":"M Vercelletto","year":"2011","unstructured":"Vercelletto M, Boutoleau-Bretonni\u00e8re C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimer Dis. 2011;23:749\u201359. First large randomized, double-blind, controlled trial of memantine in FTD patients that did not reach primary endpoints.","journal-title":"J Alzheimer Dis"},{"key":"319_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","volume":"12","author":"AL Boxer","year":"2013","unstructured":"Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149\u201356. Large multi-center, randomized, double-blind, controlled therapeutic trial demonstrating memantine lack of efficacy.","journal-title":"Lancet Neurol"},{"key":"319_CR25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","volume":"20","author":"N Hermann","year":"2012","unstructured":"Hermann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatr. 2012;20:789\u201397.","journal-title":"Am J Geriatr Psychiatr"},{"key":"319_CR26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4088\/JCP.v58n0506","volume":"58","author":"JR Swartz","year":"1997","unstructured":"Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212\u20136.","journal-title":"J Clin Psychiatry"},{"key":"319_CR27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/mds.20465","volume":"20","author":"MF Mendez","year":"2005","unstructured":"Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742\u20135.","journal-title":"Mov Disord"},{"key":"319_CR28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17482960601073543","volume":"8","author":"JM Anneser","year":"2007","unstructured":"Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler. 2007;8:189\u201390.","journal-title":"Amyotroph Lateral Scler"},{"key":"319_CR29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/jnnp.2009.173260","volume":"80","author":"CI Prodan","year":"2009","unstructured":"Prodan CI, Monnon M, Ross ED. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry. 2009;80:1416\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"319_CR30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/153331750201700504","volume":"17","author":"TW Chow","year":"2002","unstructured":"Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17:267\u201372.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"319_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000067021","volume":"49","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavioral symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13\u20139.","journal-title":"Eur Neurol"},{"key":"319_CR32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"JB Deakin","year":"2004","unstructured":"Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognitive in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharamcology (Berl). 2004;172:400\u20138.","journal-title":"Psychopharamcology (Berl)"},{"key":"319_CR33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","volume":"17","author":"F Lebert","year":"2004","unstructured":"Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemoporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"319_CR34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00004714-200006000-00018","volume":"20","author":"RC Curtis","year":"2000","unstructured":"Curtis RC, Resch DS. Case of pick\u2019s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000;20:384\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"319_CR35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15622970601016538","volume":"8","author":"A Fellgiebel","year":"2007","unstructured":"Fellgiebel A, M\u00fcller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123\u20136.","journal-title":"World J Biol Psychiatry"},{"key":"319_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.jcp.0000426190.64916.3b","volume":"33","author":"RR Reeves","year":"2013","unstructured":"Reeves RR, Perry CL. Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. J Clin Psychopharmacol. 2013;33:145\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"319_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/153331750301800410","volume":"18","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer\u2019s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205\u201314.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"319_CR38","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4088\/JCP.v69n1219a","volume":"69","author":"ED Huey","year":"2008","unstructured":"Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008;69:1981\u20132.","journal-title":"J Clin Psychiatry"},{"key":"319_CR39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/gps.774","volume":"18","author":"YA Pijnenburg","year":"2003","unstructured":"Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatr. 2003;18:67\u201372.","journal-title":"Int J Geriatr Psychiatr"},{"key":"319_CR40","first-page":"CD006625","volume":"11","author":"L Asmal","year":"2013","unstructured":"Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11: CD006625. doi: 10.1002\/14651858.CD006625.pub3 . Meta-Analysis of side effect and efficacy profile of many antipsychotics.","journal-title":"Cochrane Database Syst Rev"},{"key":"319_CR41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/WAD.0b013e318247a0bc","volume":"27","author":"E Mioshi","year":"2013","unstructured":"Mioshi E, Foxe D, Leslie F, et al. The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:68\u201373.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"319_CR42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","volume":"66","author":"ED Huey","year":"2006","unstructured":"Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17\u201322.","journal-title":"Neurology"},{"key":"319_CR43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.npp.1300886","volume":"31","author":"S Rahman","year":"2006","unstructured":"Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate (\u2018Ritalin\u2019) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"319_CR44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JCP.0b013e31823f91b9","volume":"31","author":"CE Poetter","year":"2012","unstructured":"Poetter CE, Stewart JT. Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. J Clin Psychopharmacol. 2012;31:137\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"319_CR45","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","volume":"77","author":"A Fleisher","year":"2011","unstructured":"Fleisher A, Truran D, Mai J, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011;77:1263\u201371.","journal-title":"Neurology"},{"key":"319_CR46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/WNN.0b013e31816bdf73","volume":"21","author":"M Cruz","year":"2008","unstructured":"Cruz M, Marinho V, Fontenelle LF, et al. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol. 2008;21:104\u20136.","journal-title":"Cogn Behav Neurol"},{"key":"319_CR47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/jnnp.2010.238899","volume":"83","author":"PJ Nestor","year":"2012","unstructured":"Nestor PJ. Reversal of abnormal eating and drinking behavior in a frontotemporal lobar degeneration patient using low-dose topiramate. J Neurol Neurosurg Psychiatry. 2012;83:349\u201350.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"319_CR48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1155\/2013\/547853","volume":"27","author":"C Singam","year":"2013","unstructured":"Singam C, Walterfang M, Mocellin R, et al. Topiramate for abnormal eating behavior in frontotemporal dementia. Behav Neurol. 2013;27:285\u20136.","journal-title":"Behav Neurol"},{"key":"319_CR49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1479-8301.2012.00429.x","volume":"13","author":"S Shinagawa","year":"2013","unstructured":"Shinagawa S, Tsuno N, Nakayama K. Managing abnormal eating behaviors in frontotemporal lobar degeneration in patients with topiramate. Psychogeriatrics. 2013;13:58\u201361.","journal-title":"Psychogeriatrics"},{"key":"319_CR50","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awr171","volume":"134","author":"S Jesso","year":"2011","unstructured":"Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behavior in frontotemporal dementia. Brain. 2011;134:2493\u2013501.","journal-title":"Brain"},{"key":"319_CR51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/alzrt149","volume":"4","author":"SJ Sha","year":"2012","unstructured":"Sha SJ, Boxer A. Treatment implications of C9ORF72. Alzheiemers Res Ther. 2012;4:46.","journal-title":"Alzheiemers Res Ther"},{"key":"319_CR52","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/jnnp.2009.204081","volume":"82","author":"AL Boxer","year":"2011","unstructured":"Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropatholgoical featuers of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2011;82:196\u2013203.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"319_CR53","doi-asserted-by":"crossref","unstructured":"DeJesus-Hernandez M, Mackenzie IR, et al. Expanded GGGC CC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245\u201356.","DOI":"10.1016\/j.neuron.2011.09.011"},{"key":"319_CR54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257\u201368.","journal-title":"Neuron"},{"key":"319_CR55","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. N Engl J Med. 1994;330:585\u201391.","journal-title":"N Engl J Med"},{"key":"319_CR56","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II. Lancet. 1996;347:1425\u201331.","journal-title":"Lancet"},{"issue":"2","key":"319_CR57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000114065","volume":"5","author":"HL Klawans Jr","year":"1971","unstructured":"Klawans Jr HL, Ringel SP. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol. 1971;5(2):115\u201329.","journal-title":"Eur Neurol"},{"issue":"8","key":"319_CR58","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archneur.55.8.1099","volume":"55","author":"K Kompoliti","year":"1998","unstructured":"Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55(8):1099\u2013102.","journal-title":"Arch Neurol"},{"issue":"6","key":"319_CR59","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.10211","volume":"17","author":"S Birdi","year":"2002","unstructured":"Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17(6):1255\u201364.","journal-title":"Mov Disord"},{"key":"319_CR60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/09540261.2012.751017","volume":"25","author":"K Kortte","year":"2013","unstructured":"Kortte K, Rogalski E. Behavioural interventions for enhancing life participation in behavioral variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatr. 2013;25:237\u201345. Review of non-pharmacological interventions for FTD patients.","journal-title":"Int Rev Psychiatr"},{"key":"319_CR61","unstructured":"US National Institute of Health Clinical Trials Registry 2013. Available at http:\/\/clinicaltrials.gov\/show\/NCT01835665 . Accessed 22 Aug 2014."},{"key":"319_CR62","unstructured":"US National Institute of Health Clinical Trials Registry 2013. Available at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02149160 . Accessed 22 Aug 2014."},{"key":"319_CR63","unstructured":"US National Institute of Health Clinical Trials Registry 2013. Available at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01626378 . Accessed 23 Jul 2014."},{"issue":"4","key":"319_CR64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.25815","volume":"29","author":"GU H\u00f6glinger","year":"2014","unstructured":"H\u00f6glinger GU, Huppertz HJ, Wagenpfeil S, TAUROS MRI Investigators, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014;29(4):479\u201387.","journal-title":"Mov Disord"},{"issue":"4","key":"319_CR65","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa E, Litvan I, H\u00f6glinger GU, TAUROS Investigators, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470\u20138.","journal-title":"Mov Disord"},{"issue":"2","key":"319_CR66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","volume":"80","author":"K Yanamandra","year":"2013","unstructured":"Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402\u201314.","journal-title":"Neuron"},{"key":"319_CR67","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"A Boxer","year":"2014","unstructured":"Boxer A, Lang A, Grossman M, AL-108-231 investigators. Davunetide in patients with progressive supranuclear palsy: a randomized, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 2014;13:676\u201385. Largest clinical trial of PSP to date.","journal-title":"Lancet Neurol"},{"key":"319_CR68","unstructured":"US National Institute of Health Clinical Trials Registry 2013. Available at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02133846 . Accessed 23 Jul 2014."},{"key":"319_CR69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","volume":"80","author":"CJ Donnelly","year":"2013","unstructured":"Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415\u201328.","journal-title":"Neuron"},{"key":"319_CR70","doi-asserted-by":"crossref","unstructured":"Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r(GGGG CC)-associated defects in c9FTD\/ALS. Neuron. 2014. doi: 10.1016\/j.neuron.2014.07.041 .","DOI":"10.1016\/j.neuron.2014.07.041"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-014-0319-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0319-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T06:04:25Z","timestamp":1565849065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-014-0319-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,21]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s11940-014-0319-0","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,21]]},"article-number":"319"}}